Tag: obesity

Apr 27, 2026

• glp1
• amylin
• obesity
• weight-loss
• pharm
• frontier
• investigational

Apr 27, 2026

• amylin
• obesity
• weight-loss
• pharm
• dacra
• investigational

Apr 26, 2026

• substance
• GLP-1
• amylin
• incretin
• obesity
• type-2-diabetes
• body-composition
• wearable-confounder
• investigational

Apr 26, 2026

• substance
• GLP-1
• incretin
• obesity
• metabolic-health
• type-2-diabetes
• body-composition
• wearable-confounder
• FDA-approved

Apr 26, 2026

• mechanism
• GLP-1
• amylin
• incretin
• obesity
• satiety

Apr 25, 2026

• obesity
• GLP-1
• myostatin
• activin
• lean-mass
• phase-2
• investigational
• frontier
• body-composition

Apr 25, 2026

• substance
• obesity
• GLP-1
• body-composition
• lean-mass
• myostatin
• activin
• phase-2
• investigational

Apr 25, 2026

• substance
• peptide
• dual-agonist
• glp1
• glucagon
• obesity
• type-2-diabetes
• mash
• phase-3
• investigational

Apr 24, 2026

• substance
• peptide
• glp1
• glucagon
• dual-agonist
• obesity
• mash
• t2d
• phase-3
• vitals-phase-3
• in-review

Apr 20, 2026

• obesity
• GLP-1
• myostatin
• activin
• lean-mass
• phase-2
• investigational
• frontier